Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Inoviq Ltd ( (AU:IIQ) ) is now available.
INOVIQ Ltd has secured an exclusive worldwide license from UniQuest to develop and commercialize novel exosomal biomarkers for early detection of ovarian cancer. This license supports the development of INOVIQ’s EXO-OC test, which has shown high sensitivity and specificity in detecting early-stage ovarian cancer. The company plans to commercialize the test as a Laboratory Developed Test in the US, with further global expansion following regulatory approvals. This strategic move is expected to enhance INOVIQ’s market position and potentially revolutionize ovarian cancer detection, offering significant value to stakeholders.
The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is a leader in exosome technology, focusing on next-generation diagnostics and therapeutics to transform cancer care. The company’s product portfolio includes exosome isolation products, diagnostics for ovarian and breast cancers, and a preclinical CAR-exosome therapeutic program for solid tumors.
Average Trading Volume: 109,293
Technical Sentiment Signal: Sell
Current Market Cap: A$44.09M
For a thorough assessment of IIQ stock, go to TipRanks’ Stock Analysis page.